Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Sebastian Emmanuel WillyantoYohanes Audric AlimsjahKrisanto TanjayaAekkachai TuekprakhonAulia Rahmi PawestriPublished in: Annals of medicine (2024)
Choosing a more efficacious and safer CAR T-cell treatment is crucial for improving overall survival in acute leukaemia. Beyond the promising anti-CD22 CAR T-cell, exploring costimulatory domains and new CD targets could enhance treatment effectiveness for r/r B-ALL.